Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026
Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026
Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026
Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Fineline Cube Jan 12, 2026
Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Fineline Cube Jan 12, 2026
Company Drug

CSPC Pharmaceutical’s Glumetinib Earns Breakthrough Therapy Designation in China

Fineline Cube Nov 21, 2023

Glumetinib, a MET targeted tyrosine kinase inhibitor (TKI) co-developed by CSPC Pharmaceutical Group Ltd (HKG:...

Company Medical Device

AstraZeneca Launches Evinova to Enhance Global Clinical Development with Digital Health Solutions

Fineline Cube Nov 21, 2023

UK-based AstraZeneca (AZ; NASDAQ: AZN) has launched Evinova, a digital health solutions provider, with the...

Company Drug

BMS and 2seventy Bio’s Abecma Faces FDA Review Extension

Fineline Cube Nov 21, 2023

The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...

Company Deals

Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project

Fineline Cube Nov 21, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company

Shanghai Pharmaceuticals’ Chairman Zhou Jun Resigns Amid Investigation

Fineline Cube Nov 21, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading Chinese pharmaceutical distribution company, has announced...

Company Deals

VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round

Fineline Cube Nov 21, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...

Company Drug

Jiangsu Aidea Pharmaceutical’s AINUOVIRINE Receives Priority Review Status from CDE

Fineline Cube Nov 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a Chinese pharmaceutical company, has announced that its...

Company Drug

Medilink Therapeutics’ YL201 Earns Orphan Drug Designation for Esophageal Cancer

Fineline Cube Nov 21, 2023

Suzhou-based Medilink Therapeutics has announced that it has obtained orphan drug designation (ODD) from the...

Company Deals

Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases

Fineline Cube Nov 21, 2023

Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co.,...

Company Deals

Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments

Fineline Cube Nov 21, 2023

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma...

Company Deals

Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria

Fineline Cube Nov 20, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation...

Company Deals

GE Healthcare’s Shanghai Innovation Hub Onboards Initial Start-Ups

Fineline Cube Nov 20, 2023

GE Healthcare’s (NASDAQ: GEHC) newly established Shanghai innovation center, dedicated to advancing healthcare projects, has...

Company Drug

BeiGene’s Brukinsa Secures Additional EU Approval for Follicular Lymphoma Treatment

Fineline Cube Nov 20, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has achieved its latest global approval for...

Company Deals

WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange

Fineline Cube Nov 20, 2023

WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman...

Company Deals

Winning Health Partners with Shanghai Seventh People’s Hospital on Medical AI Services

Fineline Cube Nov 20, 2023

Shanghai-based medical information industry player, Winning Health (SHE: 300253), has announced a partnership with Shanghai...

Company Deals

Thermo Fisher Scientific Expands Partnership with Sangon Biotech to Include GC/MS

Fineline Cube Nov 20, 2023

US-based life sciences giant Thermo Fisher Scientific Inc., (NYSE: TMO) has announced an expansion of...

Company Deals

Usynova Pharmaceuticals Inks Licensing Deal with AstraZeneca for KRASG12D Inhibitor UA022

Fineline Cube Nov 20, 2023

Shanghai-based Usynova Pharmaceuticals Ltd has announced a licensing agreement with UK pharmaceutical major AstraZeneca (AZ,...

Company Drug

Ascentage Pharma Secures Additional Indication Approval for Olverembatinib from NMPA

Fineline Cube Nov 20, 2023

China-based Ascentage Pharma (HKG: 6855) has announced receiving another indication approval from the National Medical...

Company

Aurobindo Pharma’s China Plant Secures EU GMP Approval, Eyes Revenue Generation

Fineline Cube Nov 20, 2023

India-based Aurobindo Pharma reportedly received EU GMP approval for its China-based manufacturing plant last week,...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Phase II Clinical Study of ALMB-0168

Fineline Cube Nov 20, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Posts pagination

1 … 382 383 384 … 607

Recent updates

  • Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study
  • Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution
  • FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development
  • Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia
  • Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Company Drug

Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.